Success Metrics

Completion Rate

0%(0/4)

Active Trials

1(14%)

Terminated

4(57%)

Phase Distribution

Ph phase_1

57%

Ph phase_2

43%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution7 total trials

Phase 1Safety & dosage

4(57.1%)

Phase 2Efficacy & side effects

3(42.9%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

0.0%

0 of 6 finished

Non-Completion Rate

100.0%

6 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(1)

Terminated(6)

Detailed Status

Terminated4

Withdrawn2

Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

0.0%

Most Advanced

Phase 2

Trials by Phase

Phase 14 (57.1%)

Phase 23 (42.9%)

Trials by Status

active_not_recruiting114%

terminated457%

withdrawn229%

Recent Activity

1 active trials

Showing 5 of 7

active_not_recruitingphase_2

Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer

NCT04390399

withdrawnphase_2

QUILT-3.067: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With TNBC Who Have Progressed on or After Standard-of-care Therapy.

NCT03387085

View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials

NCT04390399Phase 2

Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer

Active Not Recruiting

NCT03554109Phase 2

QUILT-3.057: NANT Neoadjuvant Triple- Negative Breast Cancer (TNBC) Vaccine

Withdrawn

NCT03563144Phase 2

QUILT-3.088: NANT Pancreatic Cancer Vaccine

Withdrawn

NCT03586869Phase 1

QUILT-3.080: NANT Pancreatic Cancer Vaccine

Terminated

NCT03387085Phase 1

QUILT-3.067: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With TNBC Who Have Progressed on or After Standard-of-care Therapy.

Terminated

NCT03387111Phase 1

QUILT-3.090: NANT Squamous Cell Carcinoma (SCC) Vaccine: Subjects With SCC Who Have Progressed

Terminated

NCT03387098Phase 1

QUILT-3.070:Pancreatic Cancer Vaccine: Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy

Terminated

All 7 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 7